Key points are not available for this paper at this time.
In a large real-world cohort of vedolizumab maintenance concentrations, IBD patients with remission defined by objective measures CRP and endoscopy had significantly higher trough vedolizumab concentrations and immunogenicity was uncommon.
Ungaro et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: